AHA: Lilly, Boehringer's Jardiance cuts CV hospitalizations over rival diabetes meds

In its quest to become the dominant SGLT2 diabetes med for heart failure, Eli Lilly and Boehringer Ingelheim's Jardiance has used real-world data to beat up on its GLP-1 rivals. But Jardiance isn't resting there. Now, it's touting DPP-4 inhibitor-topping data to support its case, too.